# A mathematical model for phenotypic heterogeneity in breast cancer with implications for therapeutic strategies

Xin Li<sup>1, a)</sup> and D. Thirumalai<sup>1, b)</sup>

<sup>1</sup>Department of Chemistry, University of Texas, Austin, TX 78712,

USA.

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

(Dated: 16 August 2021)

Inevitably, almost all cancer patients develop resistance to targeted therapy. Intratumor heterogeneity (ITH) is a major cause of drug resistance. Mathematical models that explain experiments quantitatively is useful in understanding the origin of ITH, which then could be used to explore scenarios for efficacious therapy. Here, we develop a mathematical model to investigate ITH in breast cancer by exploiting the observation that HER2+ and HER2- cells could divide symmetrically or asymmetrically. Our predictions for the evolution of cell fractions are in quantitative agreement with single-cell experiments. Remarkably, the colony size of HER2+ cells emerging from a single HER2- cell (or vice versa), which occurs in about four cell doublings, agrees perfectly with experimental results, without tweaking any parameter in the model. The theory quantitatively explains experimental data on the responses of breast cancer tumor under different treatment protocols. We then used the model to predict that, not only the order of two drugs, but also the treatment period for each drug and the tumor cell plasticity could be manipulated to improve the treatment efficacy. Mathematical models, when integrated with data on patients, make possible exploration of a broad range of parameters readily, which might provide insights in devising effective therapies.

<sup>&</sup>lt;sup>a)</sup>Electronic mail: xinlee0@gmail.com

<sup>&</sup>lt;sup>b)</sup>Electronic mail: dave.thirumalai@gmail.com

## 24 INTRODUCTION

Nearly 10 million people died of cancer worldwide in  $2020^1$ , despite innovations in the 25 development of many novel drugs. In principle, the advent of new technologies ought to make 26 drugs highly efficacious while minimizing toxicity. The next-generation sequencing allows 27 us to design personalized therapy, targeting specific genetic variants which drive disease 28 progression<sup>2,3</sup>. However, drug resistance ultimately occurs, regardless of targeted therapeutic 29 protocols, which poses a formidable challenge for oncologists<sup>4</sup>. A deeper understanding of 30 the underlying resistance mechanism could be useful in controlling the tumor burden and 31 its relapse. 32

Intratumor heterogeneity (ITH), which denotes the coexistence of cancer cell subpop-33 ulations with different genetic or phenotypic characteristics in a single tumor<sup>5,6</sup>, is the 34 prominent cause of drug resistance and recurrence of  $cancers^{7-9}$ . With the development 35 of deep-sequencing technologies and sequencing at the single cell level<sup>10,11</sup>, intratumor qe-36 *netic* heterogeneity has been observed in many cancer types 12-17. Meanwhile, increasing 37 evidence shows that *phenotypic* variations in tumor cells (without clear genetic alterations) 38 also play a crucial role in cancer development, and is presumed to be one of the major rea-39 sons for the development of drug resistance in cancer therapy<sup>7,18</sup>. However, the underlying 40 mechanism of ITH induced by the phenotypic variability of cancer cells is still elusive, which 41 represents an obstacle for the development of efficient treatments for cancer patients<sup>19</sup>. 42

The phenotypic heterogeneity of normal cells can emerge from cellular plasticity, which is the ability of a cell to adopt different identities. Cellular plasticity is widespread in multicellular organisms, dictating the development of organism, wound repair and tissue regeneration<sup>20–22</sup>. One of the best known examples is the differentiation hierarchies in stem cells, which leads to the production of progenitor cells, followed by the mature differentiated cells<sup>23,24</sup>.

It has been proposed that cancer might be derived from cancer stem (or initiating) cells (CSCs). The CSCs are similar to normal stem cell, but possess the ability to produce all cell types found in a tumor sample, resulting in ITH<sup>25–27</sup>. However, the prospects of a hierarchical organization, and also the unidirectional differentiation of CSCs have been challenged by recent experimental observations<sup>28–31</sup>. Some 'differentiated' cancer cells are capable of switching back to the CSCs in breast cancer<sup>28,29</sup>. Melanoma cells do not show <sup>55</sup> any hierarchically organized structure as cells are capable of switching between different <sup>56</sup> phenotypes reversibly<sup>30,31</sup>. Several models that assume reversible state transitions have been <sup>57</sup> proposed to explain the observed stable equilibrium among cancer cell subpopulations with <sup>58</sup> different phenotypes<sup>28,32</sup>. However, a detailed understanding of the underlying mechanism <sup>59</sup> driving the cell state transition is still lacking, as most previous experimental observations <sup>60</sup> are based on measurements from bulk cell populations<sup>28,29,31</sup>.

A recent insightful experiment tracked the evolution of a single circulating tumor cell 61 (CTC) derived from estrogen-receptor (ER)-positive/human epidermal growth factor recep-62 tor 2 (HER2)-negative (ER+/HER2-) breast cancer patients in vitro<sup>33</sup>. Surprisingly, HER2+ 63 cells (with expression of HER2) emerge from a cell colony grown from a single HER2- cell 64 within four cell doublings and vice versa. The single-cell level experiment demonstrates 65 that reversible transitions occurred between the two breast cancer cell types, thus provid-66 ing a clue to understanding the nature of cancer cell plasticity observed in this and other 67 experiments<sup>28,29,31,33</sup>. Because normal stem cell can differentiate into non-stem cells through 68 asymmetric cell division<sup>23</sup>, it is possible that cancer cells might also change their identity 69 by asymmetric division<sup>34</sup>, which is a potential cause of ITH. 70

We noticed that the emergence of an altered cell phenotype is to be coupled to cell divi-71 sion, as indicated by the experiments that a cell of a specific genotype produces daughter 72 cells with an altered phenotype<sup>33</sup>. Based on this observation, we developed a theoretical 73 model to describe the establishment of ITH from a single type of breast CTCs. In quanti-74 tative agreement with experiments, our model captures the tumor growth dynamics under 75 different initial conditions. It also naturally explains the emergence and evolution of ITH, 76 initiated from a single cell type, as discovered in a recent experiment<sup>33</sup>. Without adjusting 77 any free parameter in the model, we predict the evolution of cell fractions and also the 78 colony size for the appearance of HER2+ (HER2-) cell types starting from a single HER2-79 (HER2+) cell. Remarkably, the predictions agree perfectly with the experimental observa-80 tions. As a consequence of ITH, drug resistance develops rapidly, which we also reproduce 81 quantitatively. By exploring a range of parameters in the mathematical model, we found 82 that several factors strongly influence the growth dynamics of the tumor. The insights from 83 our study may be useful in devising effective therapies 33,35. 84

### 85 **RESULTS**

Drug response in a heterogeneous breast cancer cell population: To set the stage 86 for the mathematical model, we first summarize the results of experiments. It is known 87 that HER2+ cells appear in patients initially diagnosed with ER+/HER2- breast cancer 88 during treatment<sup>36,37</sup>. Although each cell subpopulation is sensitive to a specific drug, the 89 heterogeneous tumor shows varying responses for distinct treatment protocols (see Fig. 1 90 as an example). The size of an untreated tumor increases rapidly (see the green circles), 91 illustrating that a mixture of two cell types together has the ability to promote tumor growth. 92 A clear response is noted when Paclitaxel (targeting HER2+ cells) is utilized, which results in 93 reduced tumor growth (see the navy down triangles) during the treatment. Surprisingly, the 94 tumor continues to grow rapidly, with no obvious response, if treated by Notchi inhibitor (see 95 the dark yellow squares). This is unexpected as the growth of HER2- cells (sensitive to Notchi 96 inhibitor) is supposed to be inhibited by the drug. Finally, the combination therapy with 97 both the drugs, Paclitaxel and Notchi inhibitor, administered to the tumors simultaneously 98 effectively delays the tumor recurrence (see the violet up triangles). However, as both drugs gg have adverse toxic side effects on normal tissues<sup>38,39</sup>, the use of the two drugs simultaneously 100 might not be advisable. These observations suggest that instead of developing new efficacious 101 drugs, more could be done to optimize the current treatment methods<sup>40</sup>, which requires 102 an understanding of the drug resistance mechanism, and evolutionary dynamics of each 103 subpopulations quantitatively. Here, we develop a theoretical model (see Fig. 2a for the 104 illustration of the model) to explain the occurrence of phenotypic heterogeneity in breast 105 cancer, and explore diverse responses under different drug treatments (Fig. 1). 106

Phenotypic equilibrium in a heterogeneous cancer cell population: As men-107 tioned above, it is found that HER2+ and HER2- breast cancer cells transition from one phe-108 notype to another<sup>36</sup>. To demonstrate the observed cellular plasticity, fluorescence-activated 109 cell sorting (FACS)-purified HER2+ and HER2- cells were grown in culture for eight weeks 110 independently in the experiments (see SI for more experimental details)<sup>33</sup>. Surprisingly, 111 HER2- (HER2+) cell, naturally emerges from the initial HER2+ (HER2-) cell seeding within 112 four weeks. The time course of the HER2+ cell fraction,  $f_1(t)$ , is shown in Fig. 2b for differ-113 ent initial conditions. The fraction  $f_1(t)$  decreases slowly, reaching a plateau with  $f_1 \approx 78\%$ 114 after eight weeks of growth (see the green diamonds in Fig. 2b) starting exclusively from 115

HER2+ cells. On the other hand,  $f_1(t)$  increases to 63% (without reaching a plateau) from zero rapidly during the same time period, if the cell colony is seeded only from HER2- cells (see the violet squares in Fig. 2b). Finally, the HER2+ cell faction,  $f_1(t)$ , almost does not change with time if the initial population is a mixture of both cell types derived from the parental cultured CTCs directly (see the navy circles in Fig. 2b). Therefore, a steady state level (with  $f_1 \approx 78\%$ , the value in the parental cultured CTCs) is established between the two different cell phenotypes at long times, irrespective of the initial cell fraction.

To understand the experimental findings summarized in Fig. 2b, we developed a mathe-123 matical model in which the cell plasticity is coupled to cell division, as illustrated in Fig. 2a 124 (see SI for additional details). We first assume an equal rate  $K_{12} = K_{21} \equiv K_0$  for the 125 production of HER2- from HER2+ and vice versa. We also neglected the symmetric divi-126 sion  $(K_{13}, K_{31})$ , one cell producing two identical daughter cells of the other type, because 127 they rarely occur<sup>33</sup>. We found that the two rates  $(K_{12} \text{ and } K_{21})$  are small (see the follow-128 ing discussions), and it is not necessary to give different values in order to explain all the 129 experimental results. With these assumptions, Eq. (S3) in the SI can be simplified as, 130

131

$$\frac{df_1(t)}{dt} = (\Sigma - 2K_0)f_1(t) - \Sigma f_1(t)^2 + K_0 .$$
(1)

where  $f_1(t)$  is the fraction of HER2+ cell in the whole population, and  $\Sigma \equiv K_1 - K_2$ . 132 Given the initial condition,  $f_1(t=0) = 0$ , we find that  $K_0 = \frac{df_1(t)}{dt}|_{t=0}$  from Eq. (1) directly. 133 Therefore, the parameter value  $K_0 \approx 0.09$  per week is obtained using the first two data 134 points from the experiments starting with only HER2- cells (see the violet squares in Fig. 2b). 135 Finally, the value of  $\Sigma$  can be calculated from Eq. (S5) in the SI, which leads to  $\Sigma \approx 0.3$  given 136 the stable equilibrium condition  $(f_1^s = 0.78)$  found in the two cell populations in experiments 137 (see Fig. 2b). Hence, the time course of  $f_1(t)$  can be calculated by solving Eq. (1), given any 138 initial condition,  $f_1(t=0)$ , (see the two examples illustrated in Fig. 2b by green and violet 139 solid lines). Our theoretical predictions agree quantitatively with experiments, which is 140 interesting considering that we only used two experimental data points. We also found that 141 the cell fraction conversion from HER2+ to HER2- is very slow, while the reverse process 142 is rapid (see Fig. S1 and discussion in the SI). 143

Growth dynamics of cancer cell populations: The CTCs of HER2+ have a higher proliferation rate compared to HER2-, as noted both in *in vitro* and *in vivo* experiments (see the green and blue symbols in Fig. S2 in the SI). It is consistent with the predictions of our model, which shows that the rate difference,  $\Sigma \equiv K_1 - K_2 \approx 0.3$ , between the two cell types. Combined with the assumption that  $K_{12} = K_{21} \equiv K_0$ , it also explains both the fast increase in  $f_1(t)$  for the case when growth is initiated from HER2- cells, and the slowly decay of  $f_1(t)$  as initial condition is altered (Fig. 2b). The different dynamics of HER2+ cell is also associated with it being a more aggressive phenotype, including increased invasiveness, angiogenesis and reduced survival<sup>41,42</sup>.

To understand the growth dynamics of the cell populations as a function of initial condi-153 tions (Fig. S2) quantitatively, we need to determine either  $K_1$  or  $K_2$ . The other rate constant 154 can be calculated using,  $K_1 - K_2 \approx 0.3$ . Using  $K_1$  or  $K_2$ , the growth dynamics can be derived 155 directly from Eqs. (S1) - (S2) in the SI with the condition  $N(t) = N_1(t) + N_2(t)$  where  $N_1(t)$ 156 and  $N_2(t)$  are the population sizes of the two cell types. The model quantitatively describes 157 the growth behaviors of the tumor using only  $K_2 \approx 0.7$  (see the green and navy solid lines in 158 Fig. S1 in the SI) as an unknown parameter. Note that  $K_2 \approx 0.7$  implies that  $K_1 \approx 1.0$ . We 159 can also predict the growth dynamics at different initial conditions, which could be tested 160 in similar experiments. From the values of the rate constants, we would expect that the 161 frequency for symmetric cell division (the two daughter cells are identical to the parent cell) 162 is much higher than the asymmetric case for both the cell types  $(K_1 > K_2 \gg K_{12}, K_{21})$ . 163 This prediction could be tested using single cell experiments. 164

Cancer cell plasticity observed in single cell experiments: To further validate 165 the model, we calculated the percentage of HER2+/HER2- cells as a function of the cell 166 colony size starting from a single HER2+ or HER2- cell. The sizes of the cell colony have 167 been measured in experiments (see the histograms in Fig. 3)<sup>33</sup>. From Eqs. (S1) - (S2) in the 168 SI, we computed the HER2+ (HER2-) cell fraction,  $f_1(f_2)$ , as a function of the cell colony 169 size N with the initial conditions,  $N_1(t=0) = 1$  and  $N_2(t=0) = 0$  ( $N_1(t=0) = 0$  and 170  $N_2(t=0)=1$ ) using the same parameter values as given above. Our theoretical results (see 171 the solid line in Figs. 3a and 3b) are in good agreement with the experimental observations 172 without adjusting any parameter. We also found that the HER2- cell fraction  $(f_1)$  decreases 173 faster than the HER2+ cell fraction  $(f_2)$  as a function of the colony size (N), which is due 174 to the higher symmetric division rate  $(K_1 > K_2)$  of HER2+ cells. 175

Similarly, based on Eqs. (S1)–(S2) in the SI or derived from the solid lines in Figs. 3a and 3b directly, we calculated the cell colony size N, corresponding to the emergence of HER2+ cell starting from a single HER2- cell, and vice versa. The value of N is around 5 and 8 obtained from our model for HER2+ and HER2- cells, respectively. And the experimental
values are found to be 5 to 9 cells, which agrees well with our theoretical predictions.
Therefore, the model explains the experimental observation that one cell phenotype can
emerge from the other spontaneously after four cell divisions.

Quantitative description for the drug responses of HER2+ and HER2- cell 183 **populations:** We next investigated the drug response in a heterogeneous population in 184 (Fig. 1) using our model. Parameter values that are similar to the ones used to describe the 185 experimental results in vitro are used but with minimal adjustments in order to capture the 186 tumor growth observed in *in vivo* experiments. We rescaled the parameters  $K_1$  and  $K_2$  by 187 a factor (2.06), which leads to  $K_{\alpha}^{vivo} = K_{\alpha}/2.06$  with  $\alpha = 1$  or 2 (see Table 1 in the SI). 188 With these values, we found that the tumor growth dynamics in vivo is recapitulated for 189 the untreated tumor (see the green circles and dashed line in Fig. 1). 190

HER2+ cells have a higher proliferation rate (see Fig. S2 in the SI), and is sensitive 191 to cytotoxic/oxidative stress (such as Paclitaxel treatment) while the HER2- cell shows a 192 negligible response to Paclitaxel. On the other hand, Notch and DNA damage pathways are 193 activated in the HER2- cell leading to sensitivity to Notch inhibition. However, the HER2+ 194 cells are resistant to drugs for Notch inhibition<sup>33</sup>. To assess the influence of drugs on tumor 195 growth, we set the effective growth rate  $K_1^{vivo}$  ( $K_2^{vivo}$ ) of symmetric cell division to -0.5196 (the negative sign mimics the higher death rate compared to the birth rate) when the drug, 197 Paclitaxel (Notchi inhibitor), is utilized during treatment. We did not change the values of 198 the asymmetric division rate constants,  $K_{12}$  and  $K_{21}$ . 199

Following the experimental protocol, we first let the tumor grow from a parental CTCs 200 (78% of HER2+ and 22% of HER2- cells) with an initial size taken at week one. We then 201 mimicked drug treatment from the third week to the sixth week. Surprisingly, our theory 202 describes the growth dynamics of the heterogeneous tumor for different drug treatments well 203 (see the different lines in Fig. 1). Our model successfully captured the inhibition of tumor 204 growth under either Paclitaxel or the combination of Paclitaxel and Notchi inhibitor. Also 205 the weak response of tumor under the treatment of Notchi inhibitor also emerges from our 206 model naturally. 207

To understand the three distinct responses of the tumors to the drug treatments, shown in Fig. 1 further, we computed the time dependence of the tumor size in the first six weeks derived from our model with the treatment of either Notchi inhibitor or Paclitaxel (see

Figs. S3a and S3b in the SI). The tumor continues to grow rapidly without showing any 211 clear response when treated with Notchi inhibitor (see the symbols in navy in Fig. S3a), 212 inhibiting the growth of HER2- cells. Although unexpected, the observed response can 213 be explained from the cellular composition of the tumor. The fraction of HER2+ cells is 214 high (> 70%) before drug treatment, and it increases monotonically to even higher values 215  $(\sim 90\%)$  during treatment, as shown in Fig. S3c in the SI. Considering the proliferation rate 216 of HER2+ cells is higher than HER2- cells, it is clear that tumor response under Notchi 217 inhibitor only targets a minority of the tumor cell population and its reduction can be quickly 218 replenished by the rapid growth of HER2+ (see the simple illustration in Fig. S3e under the 219 treatment of Notchi inhibitor). Such a weak response is explained directly from the mean 220 fitness, the growth rate  $\omega = (K_1 + K_{12})f_1 + (K_2 + K_{21})f_2$ , landscape of the population, (see 221 Fig. S4 and detailed discussion in the SI). 222

In contrast to the negligible effect of Notchi inhibitor to the progression of the heteroge-223 neous tumor, Paclitaxel treatment that targets the HER2+ cell leads to a clear reduction 224 in the tumor size, and delays cancer recurrence (see Fig. S3b in the SI). Such a response 225 is due to the high fraction of the HER2+ cell in the tumor. It leads to the slowly growing 226 of HER2- cells, which cannot compensate for the quick loss of HER2+ cells at the start 227 of the treatment (see the rapid decay of HER2+ cell fraction in Fig. S3d and Fig. S3e for 228 illustration). However, the tumor recovers the fast growing phase in the fourth week (see 229 Fig. S3b) after the drug is used, corresponding to the time when the fraction of HER2+ 230 cell reaches around 0.5 (derived from our model with  $(0.5 - K_{12})f_1(t) = (K_2^{vivo} + K_{21})f_2(t)$ , 231 and see also Fig. S3d). Once the fraction of HER2+ cells decreases to small values, the 232 proliferation of resistant HER2- cells can compensate for the loss of HER2+ cells. Just as 233 discussed above, such a response can also be seen directly from the fitness landscape of the 234 population under treatment of Paclitaxel (see Fig. S4 and detailed discussion in the SI). 235

The fraction of HER2+ cells quickly recovers to the value in the stationary state after drug removal (see Figs. S3c and S3d), and the tumor grows aggressively again (see Fig. 1 and Fig. S3e for illustration). Therefore, the progression of the heterogeneous tumor cannot be controlled by a single drug, as demonstrated in the experiments, explained here quantitatively.

Sequential treatment strategy: Our theory, and more importantly experiments, show
that the utilization of two drugs simultaneously could significantly delay the recurrence of

tumors compared to the treatments using only a single drug of either type (see Fig. 1). However, the quantity of drugs used in the former protocol is much higher than in the latter case. Also, both drugs (Paclitaxel and Notchi inhibitor) have strong toxic side effects on normal tissues<sup>38,39</sup>. In the following, we consider a sequential treatment strategy with one drug followed by the treatment with the other, which would reduce the quantity of drugs used, and possibly reduce the toxic side effects<sup>43</sup>.

In the sequential treatment, there are two alternative methods depending on the order 249 in which the drugs are administered. We first let the tumor grows till the third week, and 250 then apply the first drug, Notchi inhibitor (Paclitaxel), from the third to the sixth week 251 followed by the utilization of the second drug, Paclitaxel (Notchi inhibitor), from the sixth 252 to the ninth week. We used the same parameter values as taken in Fig. 1. Interestingly, 253 we predict a dramatic difference between the responses of the tumors to the two treatment 254 methods (see Fig 4a). The tumor size shows no clear response to the treatment by Notchi 255 inhibitor, increasing rapidly until Paclitaxel is used (see the circles in navy in Fig. 4a and 256 a schematic illustration in the upper panel of Fig. 4c). From the phase trajectory (see the 257 circles in Fig. 4b), a rapid increase of HER2+ cell population  $(N_1)$  is found while HER2- cell 258 population  $(N_2)$  decays slowly. In contrast, just as shown in Fig. 1, a clear delay is observed 259 for the tumor growth when treated with Paclitaxel first followed by Notchi inhibitor (see 260 the diamonds in pink and navy in Fig. 4a). Meanwhile, HER2+ and HER2- cell populations 261 shrink rapidly during each drug treatment, as illustrated by the phase trajectory in Fig. 4b 262 (see the diamonds). It indicates the effectiveness of these two drugs. In addition, the tumor 263 size is always much smaller in the second protocol compared to the first, reaching three 264 fold difference in size (see the tumor size at the sixth week in Fig. 4a). It follows that 265 the order of drug administration greatly influences the treatment effects in the sequential 266 treatment method, which is consistent with recent studies  $^{43,44}$ . We also illustrate the tumor 267 response when treated with the two drugs simultaneously (see the pentagons in Fig. 4a). A 268 much better response is predicted compared to the first treatment method (see the circles in 269 Fig. 4a). However, the second approach shows a similar good response with a close tumor 270 burden at the end of treatment (see the diamond and pentagon in Fig. 4a). Hence, it is 271 possible to find an optimal strategy to obtain a similar treatment effect with attenuated side 272 effect. 273

**Effect of duration of treatment:** In the previous sections, a futile treatment with rapid

tumor growth is frequently found (see Fig. 1 or the data in Figs. 4a–4b). We surmise that 275 one drug should be removed at an appropriate time once it produces no benefits. We studied 276 the influence of treatment period length  $(\tau_d)$  on tumor responses. First, we investigated the 277 sequential treatment by Notchi inhibitor followed by Paclitaxel for different  $\tau_d$  values (see 278 Fig. 5a). The phase trajectories show that the variations in  $N_1$ , and  $N_2$  and their maximum 279 values become smaller as  $\tau_d$  is shortened. In addition, the response for each drug treatment 280 is strengthened and the total tumor size (see the inset in Fig. 5a) is always smaller for a 281 smaller  $\tau_d$ . Therefore, a small  $\tau_d$  should be used when such a treatment method is applied. 282 Next, we performed a similar analysis for the treatment with Paclitaxel first, followed 283 by Notchi inhibitor (see Figs. 5b-5c). In contrast to the situation described above, the 284 variations for  $N_1$ ,  $N_2$ , and their responses to each drug treatment are similar even as  $\tau_d$ 285 varies. However, the total population size (see the inset in Figs. 5b-5c) is smaller for the 286 two-week treatment compared to three and one-week treatment. We surmise that instead 287 of using one-week treatment for each drug, a two-week period would be a better choice in 288 this treatment strategy. Fig. 5 shows that the minimum values of  $N_1^{min}$ ,  $N_2^{min}$  (see Figs. 5a 289 and 5c) and the total minimum tumor size  $N^{min}$  (see the inset in Fig. 5) at each treatment 290 cycle increases with time, irrespective of the value of  $\tau_d$ . This would result in uncontrolled 291 tumor growth. In the following section, we will discuss potential approaches to control the 292 tumor burden even if it cannot be fully eradicated. 293

Control of tumor burden and Cellular plasticity leads to failure of treatments: 294 Despite the good response through certain treatment protocols as discussed above, tumor 295 suppression is only transient, and the tumor recurs sooner or later due to drug resistance. 296 Nevertheless, we can still seek, at least theoretically, a stable tumor burden as a compromise, 297 which is similar to the goals of adaptive therapy<sup>45</sup>. For the breast CTC consisting of HER2+ 298 and HER2- cells, the model suggests that it is possible to control the tumor maintained at 299 a constant size (with relatively small variations, see Fig. S5 and detailed discussion in the 300 SI). Finally, we have learned from our calculations that the plasticity of breast cancer cells 301 is one of the leading reasons for ITH, which in turn leads to drug resistance during therapy. 302 We investigate how such a property influences the tumor response during treatment further. 303 By varying the values of  $K_0$  ( $\equiv K_{12} = K_{21}$ ), we found that a strong transition between the 304 two cell states can lead to total failure of treatments (see Fig. S6a), while it is much easier 305 to control the tumor burden as the cellular plasticity is inhibited (see Figs. S6b-S6c and 306

more discussions in the SI). Therefore, theoretical models based on the tumor evolutionary process are likely to be useful in predicting the tumor progression, the clinical response, and possibly in designing better strategies for cancer therapy<sup>46–50</sup>.

### 310 **DISCUSSION:**

We investigated the emergence of intratumor heterogeneity in breast cancer arising from 311 cellular plasticity, which is embodied in the conversion between the HER2+ and HER2-312 phenotypes. In contrast to the unidirectional differentiation of normal stem  $cells^{51,52}$ , many 313 cancer cells demonstrate a great degree of plasticity that results in reversible transitions be-314 tween different phenotypes, leading to ITH without genetic mutations<sup>28,31</sup>. Such transitions 315 are frequently observed in rapidly growing tumors, which is often neglected in theoretical 316 models<sup>28</sup>. Although some studies have recognized the need for taking a growing population, 317 the models typically have many unknown parameters $^{32,53}$ , which are hard to interpret. 318

By introducing a direct coupling between cell division and transition between phenotypes 319 into a theoretical model, we provide a quantitative explanation for the emergence of a stable 320 ITH, a hallmark in HER-negative breast cancer patients. Our model accurately describes the 321 evolution of different cancer cell fractions, and also the total tumor size observed in a recent 322 single-cell experiment successfully. We predicted that the symmetric cell division appears 323 more frequently compared to the asymmetric case for both types of cells found in breast 324 CTCs. Without adjusting any parameter, our theoretical predictions for the cell fraction as 325 a function of the cell colony size agrees extremely well with experimental results. The cell 326 colony size (5 $\sim$ 8 cells) calculated from our theory for the emergence of one cell phenotype 327 from the other is in good agreement with the experimental observations ( $5 \sim 9$  cells). 328

The asymmetric cell division has not been observed in the breast CTC experiment di-329 rectly, although the experiment implies that cells of one phenotype produce daughters of 330 the other phenotype<sup>33</sup>. However, in a more recent experiment this was detected in breast 331 cancer<sup>34</sup>. It was found that the newly formed cell doublet, after one cell division, can be 332 the same cell type (symmetric division) or different (asymmetric division, producing two 333 daughter cells with one expressing the cytokeratin K14 while the other does not). It is also 334 possible that the state transition is not only coupled to cell division but can also appear 335 through tumor microenvironment remodeling<sup>54</sup>. However, inclusion of these processes will 336

add two more free parameters to our model, which is not needed to give the excellent agreement between theory and experiments. In addition, such a state transition is not observed after cytokinesis was inhibited in breast cancer experiment<sup>34</sup>. Nevertheless, our mathematical model could be extended to incorporate these possibilities should this be warranted in the future.

Although the asymmetric cell division explains the bidirectional state transition, the underlying mechanism for such an asymmetric division is still unclear. In the experiments<sup>28,33,34</sup>, the different states of cancer cells are mainly determined by the expression level of one or several proteins. It is possible that these proteins (HER2, K14, etc.) are redistributed in the daughter cells unequally during cell division, which could be realized through a stochastic process or regulation of other proteins<sup>34,55,56</sup>.

The reversible phenotype transitions in cells have been found in many different types 348 of cancers<sup>57–59</sup>, which not only lead to the development of drug resistance but also induce 349 very complex drug responses, as discussed here. Although each cell type is sensitive to one 350 specific drug, the heterogeneous tumor derived from breast CTC shows an obvious response 351 to Paclitaxel but not to Notchi inhibitor. Our model provides a quantitative explanation for 352 the different time courses of the tumor under distinct treatments. The failure of the Notchi 353 inhibitor, even at the initial treatment is due to its target, HER2- cell which is a minority 354 in the heterogeneous cell population, and has a slower proliferation rate compared to the 355 HER2+ cell. Both experiments and our theory show a significant delay of tumor recurrence 356 under the combination treatment with two drugs applied to the tumor simultaneously. We 357 also predict that a sequential treatment strategy with Paclitaxel first, followed by Notchi 358 inhibitor (not in a reverse order of drugs) can show similar treatment effect as the one with 359 two drugs used at the same time. In addition, the sequential treatment reduces the quantity 360 of drugs administered each time, which can reduce the adverse effects in principle<sup>43</sup>. 361

One advantage of the mathematical model is that we can steer the evolutionary dynamics of each subpopulation by applying the right drug at the appropriate time to control the tumor burden. This allows for a fuller exploration of the parameter space, which cannot be easily done in experiments. Finally, we propose that patients could benefit from drugs which inhibit the plasticity of the cancer cells<sup>34</sup>. Taken together, our model could be applied to explore ITH found in other type of cancers<sup>34,57–59</sup>. From the examples presented here and similar successful studies, we expect that the physical and mathematical models may

provide a quantitative understanding for the cancer progression and also stimulate new ideas 369 in oncology research<sup>19,46,60–62</sup>. We should emphasize that mathematical models sharpen the 370 questions surrounding the mechanisms of ITH, but real data from patients are needed to 371 understand the origins of ITH. 372

373

#### Acknowledgements 374

We are grateful to Shaon Chakrabarti, Abdul N Malmi-Kakkada, and Sumit Sinha for dis-375 cussions and comments on the manuscript. This work is supported by the National Science 376 Foundation (PHY 17-08128), and the Collie-Welch Chair through the Welch Foundation 377 (F-0019). 378

### Author contributions 379

X.L. and D.T. conceived and designed the project, and co-wrote the paper. X.L. performed 380 the research. 381

**Competing financial interests** 382

The authors declare no competing financial interests. 383

### REFERENCES 384

390

- <sup>1</sup>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global 385 cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 386
- 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021;n/a(n/a). 387
- <sup>2</sup>Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM, et al. New routes to targeted 388
- therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. The 389 oncologist. 2014;19(3):235.
- <sup>3</sup>Ellis LM, Hicklin DJ. Resistance to targeted therapies: refining anticancer therapy in the 391 era of molecular oncology. Clinical Cancer Research. 2009;15(24):7471–7478. 392
- <sup>4</sup>Ahronian LG, Corcoran RB. Strategies for monitoring and combating resistance to com-393
- bination kinase inhibitors for cancer therapy. Genome medicine. 2017;9(1):1–12. 394
- <sup>5</sup>Almendro V, Marusyk A, Polyak K. Cellular heterogeneity and molecular evolution in 395
- cancer. Annual Review of Pathology: Mechanisms of Disease. 2013;8:277–302. 396

- <sup>6</sup>Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic
  heterogeneity in cancer evolution. Nature. 2013;501(7467):338–345.
- <sup>399</sup> <sup>7</sup>Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for <sup>400</sup> cancer? Nature Reviews Cancer. 2012;12(5):323–334.
- <sup>401</sup> <sup>8</sup>Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nature
- <sup>402</sup> reviews Clinical oncology. 2018;15(2):81.
- <sup>403</sup> <sup>9</sup>Metzger Filho O, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, et al. Impact of HER2
- heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II
- <sup>405</sup> neoadjuvant clinical trial of T-DM1 combined with pertuzumab. Cancer Discovery. 2021;.
- <sup>10</sup>Koboldt DC, Steinberg KM, Larson DE, Wilson RK, Mardis ER. The next-generation
  sequencing revolution and its impact on genomics. Cell. 2013;155(1):27–38.
- <sup>408</sup> <sup>11</sup>Shapiro E, Biezuner T, Linnarsson S. Single-cell sequencing-based technologies will revolutionize whole-organism science. Nature Reviews Genetics. 2013;14(9):618–630.
- <sup>410</sup> <sup>12</sup>Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor
- <sup>411</sup> heterogeneity and branched evolution revealed by multiregion sequencing. N Engl j Med.
  <sup>412</sup> 2012;366:883–892.
- <sup>413</sup> <sup>13</sup>Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer
  <sup>414</sup> genome landscapes. Science. 2013;339(6127):1546–1558.
- <sup>14</sup>de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and
  temporal diversity in genomic instability processes defines lung cancer evolution. Science.
  2014;346(6206):251–256.
- <sup>418</sup> <sup>15</sup>Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour evolution
  <sup>419</sup> inferred by single-cell sequencing. Nature. 2011;472(7341):90.
- <sup>16</sup>Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer research.
  2012;72(19):4875-4882.
- <sup>422</sup> <sup>17</sup>Li X, Thirumalai D. Share, but unequally: a plausible mechanism for emergence
  <sup>423</sup> and maintenance of intratumour heterogeneity. Journal of the Royal Society Interface.
  <sup>424</sup> 2019;16(150):20180820.
- <sup>425</sup> <sup>18</sup>Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature.
  <sup>426</sup> 2013;501(7467):328–337.
- <sup>427</sup> <sup>19</sup>Altrock PM, Liu LL, Michor F. The mathematics of cancer: integrating quantitative
  <sup>428</sup> models. Nature Reviews Cancer. 2015;15(12):730–745.

- $_{429}$   $^{20}$  Moore KA, Lemischka IR. Stem cells and their niches. Science. 2006;311(5769):1880–1885.
- <sup>430</sup> <sup>21</sup>Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells.
- $_{431}$  nature. 2001;414(6859):105–111.
- <sup>432</sup> <sup>22</sup>Blanpain C, Fuchs E. Plasticity of epithelial stem cells in tissue regeneration. Science.
  <sup>433</sup> 2014;344(6189):1242281.
- <sup>434</sup> <sup>23</sup>Jopling C, Boue S, Belmonte JCI. Dedifferentiation, transdifferentiation and reprogramming: three routes to regeneration. Nature reviews Molecular cell biology. 2011;12(2):79–
  89.
- <sup>437</sup> <sup>24</sup>Gupta PB, Pastushenko I, Skibinski A, Blanpain C, Kuperwasser C. Phenotypic plas-
- ticity: driver of cancer initiation, progression, and therapy resistance. Cell stem cell.
  2019;24(1):65-78.
- <sup>25</sup>Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identifi cation of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences.
   2003;100(7):3983–3988.
- <sup>26</sup>Clevers H. The cancer stem cell: premises, promises and challenges. Nature medicine.
  2011;17(3):313.
- <sup>27</sup>Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell stem cell. 2014;14(3):275–
  291.
- <sup>447</sup> <sup>28</sup>Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, et al. Stochastic
  <sup>448</sup> state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell.
  <sup>449</sup> 2011;146(4):633-644.
- <sup>450</sup> <sup>29</sup>Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, et al. Normal
  <sup>451</sup> and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proceedings
  <sup>452</sup> of the National Academy of Sciences. 2011;108(19):7950–7955.
- <sup>30</sup>Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem
  cells versus clonal evolution. Cell. 2009;138(5):822–829.
- <sup>455</sup> <sup>31</sup>Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, Johnson TM, et al. Phe-
- <sup>456</sup> notypic heterogeneity among tumorigenic melanoma cells from patients that is reversible
- <sup>457</sup> and not hierarchically organized. Cancer cell. 2010;18(5):510–523.
- <sup>32</sup>Zhou JX, Pisco AO, Qian H, Huang S. Nonequilibrium population dynamics of phenotype
  <sup>conversion</sup> of cancer cells. PloS one. 2014;9(12).
- <sup>460</sup> <sup>33</sup>Jordan NV, Bardia A, Wittner BS, Benes C, Ligorio M, Zheng Y, et al. HER2 expres-

- sion identifies dynamic functional states within circulating breast cancer cells. Nature.
  2016;537(7618):102–106.
- <sup>34</sup>Granit RZ, Masury H, Condiotti R, Fixler Y, Gabai Y, Glikman T, et al. Regulation of
  <sup>464</sup> cellular heterogeneity and rates of symmetric and asymmetric divisions in triple-negative
  <sup>465</sup> breast cancer. Cell reports. 2018;24(12):3237–3250.
- <sup>35</sup>Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69–
- 468 80.
- <sup>36</sup>Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to
  mechanism-based cancer therapeutics. Cancer cell. 2014;25(3):282–303.
- <sup>37</sup>Houssami N, Macaskill P, Balleine RL, Bilous M, Pegram MD. HER2 discordance between
  primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights
  through meta-analysis. Breast cancer research and treatment. 2011;129(3):659–674.
- <sup>474</sup> <sup>38</sup>Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Kim SW, et al. In vivo evaluation of
  <sup>475</sup> polymeric micellar paclitaxel formulation: toxicity and efficacy. Journal of Controlled
  <sup>476</sup> Release. 2001;72(1-3):191–202.
- <sup>477</sup> <sup>39</sup>Tolcher AW, Messersmith WA, Mikulski SM, Papadopoulos KP, Kwak EL, Gibbon DG,
  <sup>478</sup> et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in
  <sup>479</sup> patients with refractory metastatic or locally advanced solid tumors. Journal of clinical
  <sup>480</sup> oncology. 2012;30(19):2348.
- <sup>40</sup>Eisenhauer E. Connecting communities to tackle cancer from many sides. Cell.
  <sup>2021;184(8):1949–1952.</sup>
- <sup>41</sup>Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: herceptin and beyond. European
  Journal of Cancer. 2008;44(18):2806–2812.
- <sup>42</sup>Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race,
  <sup>486</sup> breast cancer subtypes, and survival in the Carolina Breast Cancer Study. Jama.
  <sup>487</sup> 2006;295(21):2492–2502.
- <sup>43</sup>Lin KH, Rutter JC, Xie A, Pardieu B, Winn ET, Dal Bello R, et al. Using antagonistic
  pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance
  in cancer. Nature genetics. 2020;52(4):408–417.
- <sup>491</sup> <sup>44</sup>Salvador-Barbero B, Álvarez-Fernández M, Zapatero-Solana E, El Bakkali A, del
- 492 Camino Menéndez M, López-Casas PP, et al. CDK4/6 inhibitors impair recovery from

- <sup>493</sup> cytotoxic chemotherapy in pancreatic adenocarcinoma. Cancer Cell. 2020;37(3):340–353.
- <sup>494</sup> <sup>45</sup>Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer research.
  <sup>495</sup> 2009;69(11):4894–4903.
- <sup>496</sup> <sup>46</sup>Li X, Thirumalai D. Cooperation among tumor cell subpopulations leads to intratumor
  <sup>497</sup> heterogeneity. Biophysical Reviews and Letters. 2020;15(02):99–119.
- <sup>47</sup>Anderson AR, Quaranta V. Integrative mathematical oncology. Nature Reviews Cancer.
  <sup>2008;8(3):227-234.</sup>
- <sup>48</sup>Enriquez-Navas PM, Kam Y, Das T, Hassan S, Silva A, Foroutan P, et al. Exploiting
   evolutionary principles to prolong tumor control in preclinical models of breast cancer.
   Science translational medicine. 2016;8(327):327ra24–327ra24.
- <sup>49</sup>Malmi-Kakkada AN, Li X, Samanta HS, Sinha S, Thirumalai D. Cell growth rate dictates
   the onset of glass to fluidlike transition and long time superdiffusion in an evolving cell
   <sup>505</sup> colony. Physical Review X. 2018;8(2):021025.
- <sup>50</sup>Sinha S, Malmi-Kakkada AN, Li X, Samanta HS, Thirumalai D. Spatially heterogeneous
   dynamics of cells in a growing tumor spheroid: Comparison between theory and experi <sup>508</sup> ments. Soft Matter. 2020;16(22):5294–5304.
- <sup>509</sup> <sup>51</sup>Wichterle H, Lieberam I, Porter JA, Jessell TM. Directed differentiation of embryonic <sup>510</sup> stem cells into motor neurons. Cell. 2002;110(3):385–397.
- <sup>511</sup> <sup>52</sup>Keller G. Embryonic stem cell differentiation: emergence of a new era in biology and <sup>512</sup> medicine. Genes & development. 2005;19(10):1129–1155.
- <sup>53</sup>Zhou D, Wu D, Li Z, Qian M, Zhang MQ. Population dynamics of cancer cells with cell
  state conversions. Quantitative Biology. 2013;1(3):201–208.
- <sup>515</sup> <sup>54</sup>Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature. <sup>516</sup> 2001;411(6835):375-379.
- <sup>55</sup>Marantan A, Amir A. Stochastic modeling of cell growth with symmetric or asymmetric
   division. Physical Review E. 2016;94(1):012405.
- <sup>56</sup>Balázsi G, van Oudenaarden A, Collins JJ. Cellular decision making and biological noise:
   from microbes to mammals. Cell. 2011;144(6):910–925.
- <sup>57</sup>Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, et al. Rare cell
- variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature.
  2017;546(7658):431–435.
- <sup>58</sup>van Groningen T, Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N, Hasselt NE, et al.

- Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nature
   genetics. 2017;49(8):1261.
- <sup>59</sup>Ménard S, Fortis S, Castiglioni F, Agresti R, Balsari A. HER2 as a prognostic factor in <sup>528</sup>breast cancer. Oncology. 2001;61(Suppl. 2):67–72.
- <sup>60</sup>Li Х. Thirumalai D. Imprints of tumor mutation burden on chromo-529 cancer risk in humans: and relation to А pan-cancer analysis, somes 530 https://www.biorxiv.org/content/10.1101/2020.04.20.050989. bioRxiv. 2021;. 531
- <sup>61</sup>Bocci F, Gearhart-Serna L, Boareto M, Ribeiro M, Ben-Jacob E, Devi GR, et al. Toward
   <sup>533</sup> understanding cancer stem cell heterogeneity in the tumor microenvironment. Proceedings
- of the National Academy of Sciences. 2019;116(1):148-157.
- <sup>62</sup>Gatenby RA, Maini PK. Mathematical oncology: cancer summed up. Nature.
  <sup>2003;421(6921):321-321.</sup>




Figure 1: The dynamics of tumor growth under different conditions. The symbols represent results extracted from a recent experiment under four conditions<sup>33</sup>: The green circle shows the growth of mammary xenografts generated from parental CTCs (a mixture of HER2+ and HER2- cells) of breast cancer patients without any drugs. The dark yellow square and blue down triangle illustrate the tumor growth under treatment of Notchi inhibitor and Paclitaxel from the 3rd to the 6th week (indicated by the double-headed arrow), respectively. The violet up triangle corresponds to the tumor growth under treatment of both drugs simultaneously in the same period of time. The theoretical predictions for tumor growth under the four different cases are shown by the lines. The tumor is imaged using IVIS Lumina II. Its size is in the unit of the photon flux, which is proportional to the number of tumor cells.




Figure 2: The dynamics of HER2+/HER2- cells. (a) Illustration of the ITH model for breast cancer. Both HER2+ and HER2- breast circulating tumor cells (CTCs) may divide symmetrically, producing two identical HER2+ and HER2- cells with rates  $K_1$  and  $K_2$ , respectively. They can also divide in an asymmetric manner by producing one HER2+ and one HER2- cell with rates  $K_{12}$  and  $K_{21}$ . The two cell types could divide symmetrically but produce the other cell type (see the processes with rates of K13 and K31). A heterogeneous cell colony composed of both HER2+ and HER2- cells is established, irrespective of the initial cell states. (b) Experimental data for the fraction ( $f_1(t)$ ) of HER2+ cells as a function of time for three initial conditions: starting with HER2+ cells only (symbols in green), HER2- cells only (symbols in violet), and the parental cultured CTCs (symbols in navy). Theoretical predictions are shown by the solid lines. The dash dotted line for the case of parental cultured CTCs is to guide the eye.




Figure 3: The interconversion between HER2+ and HER2- cell types. (a) The HER2+ cell fraction,  $f_1$  (percentage), as a function of the total population size N in a colony grown from a single HER2+ cell. (b) The HER2- cell fraction,  $f_2$  (percentage), as a function of N as the system develops from a single HER2- cell. The error bar in y-axis gives the standard variation, while the error bar in x-axis indicates the cell number range in which the cell fraction is calculated.




Figure 4: Tumor response using a sequential protocol for two drugs. (a) Comparison of drug responses for tumors under different treatments. The green squares show tumor growth before treatment. The tumor under the treatment of Notchi inhibitor first (navy), then Paclitaxel (pink) is indicated by the circles. The diamonds show the tumor growth under the reverse order of drug treatment, Paclitaxel first (pink), followed by Notchi inhibitor (navy). The pentagons demonstrate the treatment with both drugs administered simultaneously (violet color). The pentagons in yellow show the tumor growth after the removal of all drugs. The parameter values are the same as in Fig. 1. (b) The phase trajectories for the two subpopulations,  $\text{HER2+}(N_1)$ ,  $\text{HER2-}(N_2)$ , under two sequential treatments considered in Fig. 4a, respectively. The same symbols (circle and diamond) are used in (a) and (b). The initiation of the drug treatment is indicated by the red star and the trajectory color indicating the time is shown by the color bar. The drug name during each treatment period is also listed in the figure.




Figure 5: Phase trajectories for the two subpopulations as a function of duration treatment duration. (a) Same as Fig. 4b, treated by Paclitaxel first, followed by Notchi inhibitor, except for the treatment period ( $\tau_d$ ) for each drug being one (solid line), two (dashed line) and three week (dotted line), respectively. (b) Same as Fig. 5a but treated by Paclitaxel first, then Notchi inhibitor with a three (solid line), and two-week (dashed line) treatment period for each drug, respectively. (c) Same as Fig. 5b except for the treatment period for each drug being two (dashed line), and one week (solid line), respectively. The inset shows the total number ( $N = N_1 + N_2$ ) of tumor cells as a function of time for different treatment periods.